everyone. morning, to Thanks, Baxter's to call updated financial good outlook. well on performance our provide on this Joel, as happy joining quarter as and additional morning financial details third some commentary I'm the be
our ahead are expectations. we of pleased with mentioned, our Joe in third which quarter came As results,
constant and global sales basis the and guidance. operations. from on XXXX included compared to a $XXX in X% quarter from increased on basis operations quarter and a our favorably Third continuing Sales million X% billion $X.XX discontinued reported currency
business, infusion Sales continued from better-than-expected the our drug benefited Therapies, products injectables as performance as and and strength particularly Pharmaceuticals by compounding. driven in in quarter Products in well Medical and systems sales our IV solutions
versus the $X.XX improvements, totaled a reflecting increased ongoing line, and the On decreasing interest from expense. the impact period of operational X% offset adjusted the share, by earnings operations prior bottom primarily year continuing
flat of offset and operational EPS the both higher-than-expected continuing our Adjusted aggregate, ahead continuing totaled from for came sales partially share. inclusive operations, In driven year-over-year $X.XX by adjusted expectations share, to $X.XX and operations and was per the of tax by $X.XX discontinued performance and in rate. of primarily per EPS quarter
currency Therapies, currency sales Medical X% basis. businesses division, walk through Medication Medical & in Therapies demand Within constant basis, Delivery LVP. and procedure on infusion driven were the in hardware, and portfolio, by X% Advanced Nutrition quarter benefited X% spectrum by $X and totaled includes constant totaled with the on infusion in continued Technologies reportable the growth currency and our segments. Products a strong from X grew and Now increased systems basis. performance our new Sales $X.XX million Products from billion our including a Surgery growth. Sales & line our from expectations in Therapies on Sales billion, our segment increasing pump Infusion for our which surgical a constant $XXX
Moving million. certain and a from Within $XX by sales constant were items Sales difficult constant a Kidney $XXX million, period on were X% was quarter Care, currency totaled Care. currency comparison the impacted on were basis. to that a Kidney therapies declining billion Sales the prior basis. in on year approximately flat benefited in for the to which year-over-year global $X.X discrete chronic quarter performance
consistent plans in the our of the reflect our agreement business, enhance to earlier in addition, performance U.S. sales year. the In with a and in distribution quarter exit HD this
in Finally, region performance Therapies region-specific collectively, Chronic We by due in factors pandemic. continues to impacted to patient the $XX than estimate census government-based quarter. the in sales these procurement negatively impacted million China that the initiatives more by be and lower the in
a pandemic. were XX% double-digit during following Sales growth more basis, constant reflecting business in million, regions heightened growth with on across business $XXX of for Therapies environment significant this and stabilized our Acute the representing demand a all currency
million in and For our currency to flat the $XXX were Technology & segment, prior a sales constant were the Healthcare quarter on year basis. Systems
our constant continued period. lower Care X% currency includes our and decreasing by and second contribution improve Care year more capital Systems this sequentially, Connectivity compared primarily in revenues Patient Orders sales a to hospital former on & the businesses to as basis, Solutions & division, Within within $XXX segment, Solutions the which Connectivity lower Support than spending driven XX% Surgical quarter. our prior million, a rental division from compared increasing to Solutions as were
were million, constraints. of Front the $XXX quarter basis benefit on reflecting increasing and easing Line Care sales X% supply the in currency constant a continued
During and more to $XXX able exit level. its on a expect reduce the year the to to was strength U.S. our backlog, segment backlog were million, continue we the Sales normalized quarter, X% Pharmaceuticals business in with increasing as driven within in basis. product injectables services the quarter Performance internationally. compounding launches in for new currency reflected a constant continued our demand hospital our well strong portfolio portfolio our continued by as
of increasing not the as of and sales sales level XXXX during the to following basis. third volumes of to sales million, royalty termination reduced for certain acquisition BPS a our manufacturing arrangement $XXX primarily more sales the rights declined currency This a XX% than represent which sales, reported operations, were quarter allocated a underlying XX% quarter. provided constant contract Other product. on demand discontinued segment and directly reflects and of services of facilities, the products certain lower through manufacturing include in our
Now rest P&L. the of moving to the
improvement margin materials XX.X% overhead our operations in last represented and basis increases and through improved the year-over-year able offset and XX over absorbed margin totaled partially chain of raw costs Our of ongoing the inflationary these higher reflects margin driven decline by XXX of impacts programs over basis but a pricing impact elevated were couple from prior supply continuing decline the labor integrated gross years. to cost we've We the points for year, network. sequentially. in points adjusted gross The
offset bonus higher of to of $XXX spending SG&A operational points XX accruals ongoing prior an annual year from quarter in plans sales, employee basis by Performance efficiencies, the basis R&D the prior Adjusted increase partially compensation the initiatives our or sales, a versus our benefited XX.X% prior to and totaled of compared in Adjusted the enhance year. quarter incentive year. X.X% totaled versus transformation under million XX million points the represented decrease period. $XXX of
efforts our R&D our care technologies. up in increasing ramped investments our have We particularly connected advancing
to as a enhanced second margin XXX expenses operating a of driven adjusted year the like of R&D the period. line SG&A, XX accruals factors prior points in sequential XX.X%, on expectations, points employee an versus of improved but incentive basis These impact our initiatives basis resulted to top And the our as the came margin quarter. of performance compared higher execution in Operating of include decrease prior on driving improvement ahead primarily in by efficiency. margin operating and focused compared operational
an higher increase $XX foreign on losses expectations the nonoperating million prior $X our $X million the totaled Adjusted other unfavorable period. impact in totaled in million by to the the variable exchange. versus were to year Net quarter, the prior $XXX rates income of in million driven rate interest year, compared in interest of driven by debt. mostly quarter expense Results
and primarily respect increase operational guidance, expense in was sales earnings mentioned, as in The decrease cost period. was rate driven the unfavorability prior as exchange reflecting from X% our year a interest rate of earnings With totaled XX.X% changes well impacts adjusted in adjusted expectations due mix. earnings in previously as tax better-than-expected offset well compared and quarter. efficiencies, and by higher XX% in by the inflation primarily driven goods year, the And declined to favorability negative quarter the versus sold higher-than-expected operations continuing prior partially as prior geographic as versus and to was foreign headwinds. tax by from to The FX the the $X.XX year-over-year
generated free free operations, includes year flat in of versus XXXX, prior cash months from levels. first Total compared cash in we've the flow, more track year cash of $X.XX per our to company XXXX flow remain earnings prior million the to prior year respect adjusted than to the With And period. we which share, discontinued on in period. was diluted flow operations, $XXX $XXX of double including discontinued X million,
and for XXXX, me conclude including guidance. Now by the quarter outlook our year some my remarks full key fourth let that underpinning discussing assumptions
year constant XXXX, a expects sales on reported Baxter X% currency full X% approximately on basis growth a of continuing operations to For total X% from and basis.
exchange is on basis, a margin Foreign results year of On be continuing operating full XX.X% adjusted operations a to basis expected full expect to headwind basis. XX point XX.X%. year an we to approximate reported
expense transaction in net million closing of the and a reduction $XX fourth payout, we BPS of the interest quarter. approximately related With expect debt of the
be For the expect we interest net $XXX year, approximately expense million. full to
tax we full share. of anticipate average $X.XX XX%. adjusted now diluted to XXX rate of year to per earnings $X.XX We expect a XX.X% share adjusted full We And operations count year of from continuing lastly, million expect shares.
fourth we sales adjusted to growth on currency the of reported a global $X.XX basis. to excluding earnings, and quarter Specific approximately on expect approximately constant XXXX diluted special $X.XX a share. of we basis X% to of And items, per expect X% X%
the up open now can call we for Q&A. that, With
